menu
Contact
our partners

JLABS @ NYC
101 6th Ave,
New York, NY 10013

​​

Cambridge Innovation Center
1 Broadway 
Cambridge, MA 02142
Boston

Info@Atoms2applications.com

Wuxi.PNG
biomea.PNG
insilico.png
Charles-River.png

© 2019 A2A Pharma. All rights reserved

PHARMACEUTICALS

FOCUSED ON AI

& NOVEL DRUG

ALTERNATIVES

LEADERS

IN DRUG

DESIGN

Wuxi.PNG

OUR PARTNERS

biomea.PNG
Charles-River.png
insilico.png

At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems, including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.

Significant Achievements to Date

Partnership with Insilico Medicine to develop a novel therapeutics for Duchenne Muscular Dystrophy. 

Won the J&J Innovation Artificial Intelligence Challenge for drug discovery.

Enter into 50/50 partnerships with

former management of Pharmacyclics  to advance the leukemia program

into Phase I studies in 2019.

2018

2017

Raised a total of $5 million in financing. 

Revenue generating pilot projects with Novartis and Proctor & Gamble to sign new drug candidates.

2016

Seed funding through SOSV and incubation at IndieBio.

PIPELINE

Focus indications are in difficult to drug targets,  including protein-protein interactions, in leukemia and other solid tumor cancers, as well as Muscular Dystrophy and drug-resistant bacterial infections. 

Robust Development Pipeline & Partnerships

Programs

Oncology

MLL-Menin

(Leukemia)

Yap-Tead*

(Solid Tumors)

STING*

(Tumor Myeloid cells)

RAS*

(Protein Degradation)

Additional Programs

CLK

(Cancer & DMD)

LpxC

(Gram - Bacteria)

Collaboration

Cardiovascular

Oncology

Target

Identification

In-Silico

Pre-Optimization

Testing

Synthesis

Lead

Identification

Lead

Optimization

Pre-IND

Studies

IND

Potential

Market

2019

2021

 

2022

 

 

2022

 

 

 

2020

 

 

2021

$1B

$5B

$1B

$5B

$3B

$1B

Partnerships with Novartis and Proctor & Gamble to design drug candidates for cardiavascular and cancer targest

TECHNOLOGY

Sculpt.png